On May 30, 2024 BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR)-based therapies with a robust clinical pipeline and powerful, high-throughput TCR identification and screening platform, TCXpress, reported that Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio, will provide a corporate update and participate in a panel discussion at the 2024 BIO International convention being held from June 3 – 6, 2024 in San Diego, California (Press release, BlueSphere Bio, MAY 30, 2024, https://bluespherebio.com/press_release/bluesphere-bio-to-present-corporate-update-and-participate-in-a-panel-discussion-at-the-2024-bio-international-convention/ [SID1234643845]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The corporate update will highlight BlueSphere’s progress towards its first clinical program in high-risk leukemia and clinical development efforts of its first-in-human candidate, BSB-1001. BSB-1001 is the first TCR-based clinical candidate identified using TCXpress that targets the minor histocompatibility antigen-1 (HA-1). This first-in-human study will deploy BSB-1001 in combination with standard of care allogeneic stem cell transplant. In addition, BlueSphere will provide updates on additional upcoming clinical programs and discovery efforts utilizing its TCXpress platform.
In the panel discussion, which will be moderated by Angus Liu, Deputy Editor of Fierce Pharma/Fierce Biotech, experts will address the future of T cell-directed cancer therapies. Topics covered will include new applications for treating more patients with this approach, overcoming ongoing biological challenges in solid tumors, high relapse rates, manufacturing, and costs.
Corporate update and panel details can be found below.
Corporate update details:
Track: Cell and Gene Therapy and Genome Editing
Date: Tuesday, June 4, 2024
Time: 1:45 – 2:00 p.m. PT
Location: San Diego Convention Center; Theater 4
Panel details:
Title: What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
Date: Thursday, June 6, 2024
Time: 9:00 a.m. – 10 a.m. PST
Location: San Diego Convention Center; Room 24BC
Moderator: Angus Liu, Senior Writer at Fierce Pharma and Fierce Biotech
Session details can be found here and to register for the 2024 BIO International convention, visit their website here.